Abstract
We report the results of the evaluation of a series of benzyl imidazole-based compounds against the enzyme aromatase (AR). The results show that the synthesised compounds were potent inhibitors of AR in comparison to the standard compound aminoglutethimide (AG).
Keywords: Enzyme, Inhibition, Azole, Estrogen synthetase, Aromatase
Letters in Drug Design & Discovery
Title: Inhibition of Aromatase (AR) by Benzyl Azole-Based Compounds
Volume: 4 Issue: 8
Author(s): Shaheen Adat, Caroline P. Owen and Sabbir Ahmed
Affiliation:
Keywords: Enzyme, Inhibition, Azole, Estrogen synthetase, Aromatase
Abstract: We report the results of the evaluation of a series of benzyl imidazole-based compounds against the enzyme aromatase (AR). The results show that the synthesised compounds were potent inhibitors of AR in comparison to the standard compound aminoglutethimide (AG).
Export Options
About this article
Cite this article as:
Adat Shaheen, Owen P. Caroline and Ahmed Sabbir, Inhibition of Aromatase (AR) by Benzyl Azole-Based Compounds, Letters in Drug Design & Discovery 2007; 4 (8) . https://dx.doi.org/10.2174/157018007782794554
DOI https://dx.doi.org/10.2174/157018007782794554 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Carbohydrate-Based Bioactive Compounds for Medicinal Chemistry Applications
Mini-Reviews in Medicinal Chemistry Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Cancer Stem Cells Stemness Transcription Factors Expression Correlates with Breast Cancer Disease Stage
Current Stem Cell Research & Therapy Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Green Reduction of Graphene Oxide into Graphene by Cow Urine
Current Nanomaterials Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Design of Ru-arene Complexes for Antitumor Drugs
Mini-Reviews in Medicinal Chemistry Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design